Rocab 60/10 mg Tablets
Fimasartan Potassium Trihydrate Granules 150mg · Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication · Combination
Boryung Biopharma Co., Ltd.
MFDS item code 201700491 · Approved 2017.01.25
Treatment of hypertension, improvement of dyslipidemia, inhibition of atherosclerosis progression and cardiovascular disease risk
This medication is used for patients who need to take both Pimasartan and Rosuvastatin simultaneously. Pimasartan is primarily used to treat essential hypertension and helps control blood pressure. Rosuvastatin is mainly used to improve hypercholesterolemia and various types of dyslipidemia, and is used as an adjunct if dietary changes and exercise are insufficient. It also helps reduce the risk of cardiovascular diseases, thereby lowering the risk of stroke, myocardial infarction, and arterial revascularization. This medication is effectively used to improve the health of patients with both hypertension and dyslipidemia.
This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, fimasartan/rosuvastatin. ○ Fimasartan 1. Adults The recommended dose is 30~60 milligrams once daily, administered regardless of food. If blood pressure is not adequately controlled at this dose, it may be increased to 120 milligrams once daily. If possible, it is recommended to take the medicine at the same time each day (e.g., in the morning). The antihypertensive effect appears within 2 weeks after starting treatment and reaches its maximum effect after approximately 8 weeks~12 weeks. 2. Older adults No initial dosage adjustment is required for older adults up to 70 years of age. 3. Patients with renal impairment No dosage adjustment is required in patients with mild to moderate renal impairment (creatinine clearance 30~80 mL/min). In patients with severe renal impairment (creatinine clearance < 30 mL/min), initiate treatment at 30 milligrams once daily and do not exceed 60 milligrams daily. 4. Patients with hepatic impairment No dosage adjustment is required in patients with mild hepatic impairment. Do not administer this medicine to patients with moderate to severe hepatic impairment. 5. Patients with reduced effective circulating blood volume (e.g., patients taking high doses of diuretics) For patients at high risk of hypotension, such as those with reduced effective circulating blood volume, an initial dose of 30 milligrams once daily is recommended. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; if a greater reduction in LDL cholesterol is required, adjust the dose to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. Adjust the maintenance dose as appropriate at intervals of 4 weeks or more according to LDL cholesterol levels, treatment goals, and patient response; it may be increased to a maximum of 20 milligrams daily. 2. Older adults No dosage adjustment is required. 3. Patients with renal failure No dosage adjustment is required in patients with mild or moderate renal failure. Do not administer to patients with severe renal failure. Use particular caution when administering 20mg of this medicine to patients with moderate renal failure. 4. Patients with hepatic failure No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score above 9. Do not administer this medicine to patients with active liver disease. 5. Race Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. Patients taking fimasartan and rosuvastatin concomitantly may switch to this medicine (a fixed-dose combination containing the same amounts of each active ingredient) for convenience.
This medication may cause serious harm to the fetus and newborn if taken during pregnancy, especially during the second and third trimesters, so it should be stopped immediately upon confirmation of pregnancy. It is contraindicated for women who are allergic to this medication, pregnant or breastfeeding women, patients with severe liver disease, and patients with significantly impaired kidney function. Patients with very low blood pressure, weak kidney function, specific heart conditions, or muscle disease should use this medication with caution and be closely monitored. Since this medication can affect the liver and muscles, any symptoms of muscle pain, muscle weakness, or abnormal liver function during treatment should be reported to medical personnel immediately. As this is an antihypertensive medication, low blood pressure symptoms may occur shortly after starting treatment, particularly in patients who are dehydrated or taking diuretics. This medication may interact with other drugs, so anyone taking other medications should inform their healthcare provider, particularly in the case of potassium-sparing diuretics or certain antibiotics and antifungals. Regular monitoring of liver function, serum potassium levels, and muscle enzyme levels is recommended during treatment. Women of childbearing potential should use appropriate contraception while taking this medication and should not take it if planning to become pregnant or during pregnancy. Elderly patients may react sensitively to this medication, thus careful dosage adjustment and monitoring of their condition are necessary. The safety and efficacy of this medication have not been established for children and adolescents under 18 years of age. Dizziness or drowsiness may occur after taking this medication, so caution should be exercised when driving or operating dangerous machinery. When storing this medication, keep it out of reach of children, and do not transfer it to another container.
Dyspepsia, nausea, fever, hepatitis, headache, dizziness, upper abdominal pain, esophagitis, gastritis, nasopharyngitis, tonsillitis, upper respiratory infection, elevated ALT, elevated γ-GTP, elevated liver enzyme levels, increased leukocyte count, urinary disturbance, frequent urination, cough, hyperkalemia, arthralgia, insomnia, pruritus, syncope, sedation, migraine, vomiting, weakness, foreign body sensation, decreased platelet count, increased serum creatine phosphokinase, muscle contraction, musculoskeletal stiffness, facial flushing, flushing, erectile dysfunction, constipation, abdominal pain, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, memory loss, peripheral neuropathy, jaundice, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, nightmares, sexual dysfunction, gynecomastia, fatal and non-fatal hepatic failure, cognitive impairment, severe muscle weakness, ocular myasthenia, acute pancreatitis, intestinal obstruction, hemorrhagic duodenal ulcer, appendicitis, hemorrhoids, abdominal pain, intracranial hemorrhage, transient ischemic attack, atherosclerosis, cerebral infarction exacerbation, cerebral hemorrhage, liver cancer, colon carcinoma, neoplasm of unspecified nature, cervical cancer, prostate cancer, acute kidney failure, chronic kidney failure, kidney stones, pyelonephritis, urinary incontinence, rhinitis, fibrosing alveolitis, pharyngitis, pneumonia, lung disease, death, worsening lower back pain, osteoarthritis, arthrosis, hypoglycemia, pulmonary embolism, purpura, bradycardia, atrial fibrillation, coronary artery disease, aortic stenosis, heart failure, hypertension, acute hepatitis, benign pituitary neoplasm, otitis media, uterine prolapse, recurrent cancer, chest pain, low back pain, limb pain, peripheral edema, facial swelling, fatigue, fever, neck/shoulder pain, fracture, arthralgia, osteoporosis, myalgia, pharyngitis, upper respiratory infection, sputum, rhinitis, epistaxis, bronchitis, sensory disturbance, numbness, tremor, hypertonia, anxiety, memory impairment, loss of appetite, gastroesophageal reflux, gastritis, diarrhea, constipation, functional gastrointestinal disorders, gastroenteritis, frequent urination, urinary incontinence, kidney stones, chronic kidney failure, dysuria, hyperlipidemia, dyslipidemia, hypoglycemia, cerebral infarction, shingles, visual disturbances, tachycardia, hypertension, fatty liver, localized inflammation, soft tissue inflammation, lymphadenopathy, abrasion of unspecified nature, septal deviation, surgical intervention, postoperative pain, heat intolerance, fall, postoperative pain, contusion
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air or moisture, so it should be stored in a tightly sealed container. It is recommended to keep the storage temperature between 1 degree and 30 degrees Celsius at room temperature to maintain the efficacy and safety of the medication.
Orange, convex, octagonal film-coated tablets
30 tablets (10 tablets/PTP package X 3), 100 tablets (10 tablets/PTP package X 10)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Fimasartan Potassium Trihydrate Granules 150mg · Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication · Combination
Boryung Biopharma Co., Ltd.
CombinationFimasartan Potassium Trihydrate Granules 150mg · Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication · Combination
Boryung Co., Ltd.
CombinationFimasartan Potassium Trihydrate Granules 150mg · Rosuvastatin Calcium 5.2mg
Tablet · Prescription medication · Combination
Boryung Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate Granules 300mg · Rosuvastatin Calcium 20.8mg
Tablet · Prescription medication · Combination
Boryung Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate Granules 75mg · Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication · Combination
Boryung Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate Granules 75mg · Rosuvastatin Calcium 5.2mg
Tablet · Prescription medication · Combination
Boryung Pharmaceutical Co., Ltd.
Fimasartan Potassium Trihydrate Granules 75mg · Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication · Combination
Boryung Biopharma Co., Ltd.
Fimasartan Potassium Trihydrate Granules 75mg · Rosuvastatin Calcium 5.2mg
Tablet · Prescription medication · Combination
Boryung Biopharma Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.